Skip to main content

Table 1 Clinical and demographic parameters of patients with rheumatoid arthritis

From: Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment

Parameter Post-rituximab
(n = 11)
Pre-rituximab
(n = 8)
Controls
(n = 10)
Vaccination time 6 months after RTX 6 days before RTX No RTX
B cells (% of mononuclear cells in circulation) (mean ± SD) 2.2 ± 5.2 4.7 ± 4.1 6.1 ± 2.9
Age, years
(mean ± SD, range)
60.4 ± 7.8
(45-70)
65.4 ± 11.5
(55-82)
63.6 ± 12.9
(48-95)
Gender, m/f 1/10 1/7 3/7
Disease duration, years
(range)
17.3 ± 13.1
(6-33)
8.6 ± 5.5
(3-18)
7.4 ± 4.6
(2-16)
Erosive 10 (91%) 7 (87%) 9 (90%)
RF, positive 11 8 10
Treatment    
MTX, n (mg/week, mean ± SD) 10 (17.7 ± 6.3)a 7 (18.7 ± 5.4)b 10 (18.3 ± 5.6)
Previous anti-TNF, n 10 5 2
Previous RTX, n 4 1 0
Time after previous RTX, months 30 months
(14-48)
24 months 0
  1. MTX, Methotrexate; RF, rheumatoid factor; RTX, rituximab; SD, standard deviation; TNF, tumor necrosis factor.
  2. aOne patient was receiving azathioprine treatment.
  3. bOne patient was receiving chlorambucil treatment.